Previous Article | Next Article 
Journal of Clinical Microbiology, November 2003, p. 5282-5284, Vol. 41, No. 11
0095-1137/03/$08.00+0 DOI: 10.1128/JCM.41.11.5282-5284.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.
Bacitracin-Resistant Clone of Streptococcus pyogenes Isolated from Pharyngitis Patients in Belgium
Surbhi Malhotra-Kumar,* Shuang Wang, Christine Lammens, Sabine Chapelle, and Herman Goossens
Department of Microbiology, University of Antwerp (UIA), Antwerp, Belgium
Received 6 June 2003/
Returned for modification 28 July 2003/
Accepted 14 August 2003

ABSTRACT
We report 16 bacitracin-resistant
Streptococcus pyogenes isolates
recovered from pharyngitis patients in Belgium, 14 of which
belonged to a particular
emm type (
emm28). All 16 isolates were
constitutively resistant to macrolides and carried
erm(B). The
emergence of a bacitracin-resistant
S. pyogenes clone raises
questions about the continued reliability of bacitracin susceptibility
testing for
S. pyogenes identification.

TEXT
Streptococcus pyogenes, a Lancefield group A streptococcus,
is a common pathogen in humans, causing tonsillo-pharyngitis
and serious invasive infections, such as necrotizing fasciitis
and toxic shock syndrome. The prevalence of
S. pyogenes infections
has increased drastically in the last decade (
4,
8) and correlates
with increasing resistance to macrolide and tetracycline groups
of antibiotics, which act by disrupting prokaryotic protein
synthesis (
2,
3,
6). However,
S. pyogenes has remained uniformly
susceptible to antibiotics that disrupt cell wall synthesis:
i.e., penicillins, glycopeptides, and bacitracin. In fact, susceptibility
to bacitracin is one of the preliminary laboratory tests employed
in the presumptive differentiation of
S. pyogenes from other
beta-hemolytic streptococci. We report here 16 bacitracin-resistant
isolates recovered from tonsillo-pharyngitis patients as part
of a national surveillance study conducted in Belgium during
2002. These isolates were investigated further for clonality,
as well as resistance to macrolides and other antibiotic groups.
A total of 1,572 presumptive S. pyogenes isolates were collected from 10 Belgian provinces. Of these, 1,229 isolates were confirmed to be S. pyogenes on the basis of a battery of tests: beta-hemolysis on blood agar, Gram stain, catalase, pyrrolidonyl aminopeptidase (PYR), group A antigen, and the bacitracin disk diffusion test (0.4 U; Rosco, Taastrup, Denmark). All S. pyogenes isolates showed the expected results, except for 16 isolates that showed resistance to bacitracin (disk diffusion zone diameters of 0 mm). Macrolide resistance for these isolates was determined by the conventional double-disk diffusion test with erythromycin (78 µg) and clindamycin (25 µg) Neo-Sensitab disks (Rosco), and the results were interpreted as reported previously (7). MICs of erythromycin, clarithromycin (Abbott, Ottignies, Belgium), azithromycin (Pfizer, Groton, Conn.), clindamycin and telithromycin (Aventis, Romainville, France), penicillin and ciprofloxacin (Bayer AG, Leverkusen, Germany), and tetracycline were determined by the agar dilution method. The inoculum (104 CFU/spot) was incubated under aerobic conditions at 37°C for 18 to 24 h, and the results were interpreted according to National Committee for Clinical Laboratory Standards guidelines. For telithromycin, breakpoints of susceptibility and resistance were taken as
1 and
4 µg/ml, respectively. Unless specifically mentioned, antibiotics were purchased from Sigma Chemical Co. (St. Louis, Mo.). In addition, the presence of the macrolide resistance determinants erm(B), mef(A), and erm(A) was detected by PCR. Genomic DNA was extracted by the alkaline lysis method (0.25% sodium dodecyl sulfate, 0.05 N NaOH). PCR was performed with a DNA thermal cycler (9600 GeneAmp PCR system; Perkin-Elmer, Zaventem, Belgium). The primers described previously for erm(B) and mef(A) give PCR products of 639 and 348 bp (9), respectively, while a 590-bp product was obtained with the following primers for erm(A): 5' CCCGAAAAATACGCAAAATTTCAT 3' and 5' CCCTGTTTACCCATTTATAAACG 3' (G. Cornaglia, personal communication). The PCR mix and cycling conditions for erm(B), and mef(A) were described previously (2). For erm(A), each 50-µl PCR mixture contained 50 mM KCl, 10 mM Tris-HCl (pH 9.0), 0.1% Triton X-100, 0.01% gelatin, 200 µM deoxynucleoside triphosphates (dNTPs), 1.5 mM MgCl2, 20 pmol of primers, 0.45 U of SuperTaq polymerase (Enzyme Technologies Ltd., United Kingdom), and 2 µl of template DNA. The cycling conditions were an initial cycle of 5 min at 94°C; 35 cycles of 30 s of denaturation at 90°C, 60 s of annealing at 60°C, and 90 s of extension at 72°C; and finally 1 cycle of 5 min of elongation at 72°C. Positive controls used for erm(A), erm(B), and mef(A) were S. pyogenes strains UR1092, STP016, and STP046, respectively. Clonality was studied by pulsed field gel electrophoresis (PFGE) as well as emm typing as described previously (2, 5).
All 16 bacitracin-resistant S. pyogenes strains demonstrated constitutive resistance to erythromycin and clindamycin, explained by the uniform presence of the erm(B) gene. Neither mef(A) nor erm(A) was detected in any isolate. For these 16 isolates, the MICs at which 90% of the isolates tested are inhibited of erythromycin, clindamycin, clarithromycin, azithromycin, telithromycin, tetracycline, penicillin, and ciprofloxacin were >512, >512, 512, >512, 8, 0.125, 0.01, and 0.5 µg/ml, respectively. The PFGE clusters correlated completely with the emm typing results. Most interestingly, of the 16 isolates, 14 belonged to one PFGE cluster (10) and 1 particular emm type (emm28), and 2 isolates belonged to a distinct non-emm-typeable PFGE cluster (Fig. 1). Of the 14 clonal isolates, 13 were isolated from patients residing in the southern Belgian provinces of Hainaut, Luxembourg, and Liège, while 1 isolate was from the northern province of Vlaams-Brabant.
So far, there has only been a single published report of a bacitracin-resistant
S. pyogenes clone that was recovered from invasive infections
(
11), indirectly suggesting that bacitracin resistance could
be related to invasiveness. However, our findings of bacitracin-resistant
S. pyogenes from pharyngitis patients suggest that there is
no link between bacitracin resistance and invasiveness. Interestingly,
both the earlier report (
11) and this study show that the majority
of the bacitracin-resistant
S. pyogenes isolates are clonal.
Although no gene was ascribed to macrolide resistance in the
previous study (
11), macrolide resistance in our clone was explained
by the presence of
erm(B). Moreover, the
emm28 bacitracin-resistant
clone was concentrated in southern Belgian provinces. We are
currently investigating whether the presence of such strains
could be related to the use of non-prescription-based bacitracin-containing
throat lozenges. Also, efforts to elucidate the mechanism of
bacitracin resistance in the
emm28 clone are under way. Since
bacitracin acts by preventing dephosphorylation and recycling
of a lipid carrier (undecaprenol pyrophosphate), resistance
to bacitracin, although not definitively characterized, is believed
to result from an overproduction of undecaprenol kinase encoded
by the
bacA gene (reviewed in reference
1). Regardless of the
precise reason for the resistance, a further search for bacitracin-resistant
S. pyogenes isolates warrants that a preliminary screening for
S. pyogenes should not rely on susceptibility to bacitracin.

ACKNOWLEDGMENTS
We thank the following Belgian centers for their participation
in this study: AML BVBA, Antwerp; Laboratoire de Biologie Clinique
et Hormonale-S.P.R.L., Couillet; Centraal Laboratorium, Hasselt;
Medisch Centrum Huisarten, Leuven; Centre Hospitalier de L'Ardenne
Laboratoire de Biologie Clinique et de Ria, Libramont; and Laboratoire
Marchand, Liège.

FOOTNOTES
* Corresponding author. Mailing address: Department of Medical Microbiology, University of Antwerp, S3, Universiteitsplein 1, B-2610 Wilrijk, Belgium. Phone: 32-3-820-25-51. Fax: 32-3-820-26-63. E-mail:
surbhi{at}uia.ua.ac.be.


REFERENCES
1 - Butaye, P., L. A. Devriese, and F. Haesebrouck. 2003. Antimicrobial growth promoters used in animal feed: effects of less well known antibiotics on gram-positive bacteria. Clin. Microbiol. Rev. 16:175-188.[Abstract/Free Full Text]
2 - Descheemaeker, P., S. Chapelle, C. Lammens, M. Hauchecorne, M. Wijdooghe, P. Vandamme, M. Ieven, and H. Goossens. 2000. Macrolide resistance and erythromycin resistance determinants among Belgian Streptococcus pyogenes and Streptococcus pneumoniae isolates. J. Antimicrob. Chemother. 45:167-173.[Abstract/Free Full Text]
3 - Jasir, A., A. Tanna, A. Noorani, A. Mirsalehian, A. Efstratiou, and C. Schalen. 2000. High rate of tetracycline resistance in Streptococcus pyogenes in Iran: an epidemiological study. J. Clin. Microbiol. 38:2103-2107.[Abstract/Free Full Text]
4 - Kaplan, E. L. 1991. The resurgence of group A streptococcal infections and their sequelae. Eur. J. Clin. Microbiol. Infect. Dis. 10:55-57.[CrossRef][Medline]
5 - Kaufhold, A., A. Podbielski, G. Baumgarten, M. Blokpoel, J. Top, and L. Schouls. 1994. Rapid typing of group A streptococci by the use of DNA amplification and non-radioactive allele-specific oligonucleotide probes. FEMS Microbiol. Lett. 119:19-25.[CrossRef][Medline]
6 - Seppala, H., A. Nissinen, H. Jarvinen, S. Huovinen, T. Henriksson, E. Herva, S. E. Holm, M. Jahkola, M. L. Katila, and T. Klaukka. 1992. Resistance to erythromycin in group A streptococci. N. Engl. J. Med. 326:292-297.[Abstract]
7 - Seppala, H., A. Nissinen, Q. Yu, and P. Huovinen. 1993. Three different phenotypes of erythromycin-resistant Streptococcus pyogenes in Finland. J. Antimicrob. Chemother. 32:885-891.[Free Full Text]
8 - Stevens, D. L. 1995. Streptococcal toxic-shock syndrome: spectrum of disease, pathogenesis, and new concepts in treatment. Emerg. Infect. Dis. 1:69-78.[Medline]
9 - Sutcliffe, J., T. Grebe, A. Tait-Kamradt, and L. Wondrack. 1996. Detection of erythromycin-resistant determinants by PCR. Antimicrob. Agents Chemother. 40:2562-2566.[Abstract]
10 - Tenover, F. C., R. D. Arbeit, R. V. Goering, P. A. Mickelsen, B. E. Murray, D. H. Persing, and B. Swaminathan. 1995. Interpreting chromosomal DNA restriction patterns produced by pulsed-field gel electrophoresis: criteria for bacterial strain typing. J. Clin. Microbiol. 33:2233-2239.[Medline]
11 - York, M. K., L. Gibbs, F. Perdreau-Remington, and G. F. Brooks. 1999. Characterization of antimicrobial resistance in Streptococcus pyogenes isolates from the San Francisco Bay area of Northern California. J. Clin. Microbiol. 37:1727-1731.[Abstract/Free Full Text]
Journal of Clinical Microbiology, November 2003, p. 5282-5284, Vol. 41, No. 11
0095-1137/03/$08.00+0 DOI: 10.1128/JCM.41.11.5282-5284.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.
This article has been cited by other articles:
-
Malhotra-Kumar, S., Mazzariol, A., Van Heirstraeten, L., Lammens, C., de Rijk, P., Cornaglia, G., Goossens, H.
(2009). Unusual resistance patterns in macrolide-resistant Streptococcus pyogenes harbouring erm(A). J Antimicrob Chemother
63: 42-46
[Abstract]
[Full Text]
-
Perez-Trallero, E., Montes, M., Orden, B., Tamayo, E., Garcia-Arenzana, J. M., Marimon, J. M.
(2007). Phenotypic and Genotypic Characterization of Streptococcus pyogenes Isolates Displaying the MLSB Phenotype of Macrolide Resistance in Spain, 1999 to 2005. Antimicrob. Agents Chemother.
51: 1228-1233
[Abstract]
[Full Text]
-
Malhotra-Kumar, S., Lammens, C., Piessens, J., Goossens, H.
(2005). Multiplex PCR for Simultaneous Detection of Macrolide and Tetracycline Resistance Determinants in Streptococci. Antimicrob. Agents Chemother.
49: 4798-4800
[Abstract]
[Full Text]
-
Manson, J. M., Keis, S., Smith, J. M. B., Cook, G. M.
(2004). Acquired Bacitracin Resistance in Enterococcus faecalis Is Mediated by an ABC Transporter and a Novel Regulatory Protein, BcrR. Antimicrob. Agents Chemother.
48: 3743-3748
[Abstract]
[Full Text]
-
Mihaila-Amrouche, L., Bouvet, A., Loubinoux, J.
(2004). Clonal Spread of emm Type 28 Isolates of Streptococcus pyogenes That Are Multiresistant to Antibiotics. J. Clin. Microbiol.
42: 3844-3846
[Abstract]
[Full Text]
-
Malhotra-Kumar, S., Lammens, C., Martel, A., Mallentjer, C., Chapelle, S., Verhoeven, J., Wijdooghe, M., Haesebrouck, F., Goossens, H.
(2004). Oropharyngeal carriage of macrolide-resistant viridans group streptococci: a prevalence study among healthy adults in Belgium. J Antimicrob Chemother
53: 271-276
[Abstract]
[Full Text]